Sage Therapeutics’ stock plunges as Parkinson’s drug trial disappoints

Sage Therapeutics shares dropped early Wednesday after the company said its experimental treatment for mild cognitive impairment in patients with Parkinson’s disease fell flat in a clinical trial.

Source: MarketWatch

Continue reading...